BCM
SPHS

Bourgeon Capital Management’s Sophiris Bio, Inc. SPHS Stock Holding History

Bourgeon Capital Management’s Portfolio SPHS Stock Details SPHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10,000
Closed -$31K – 107
2016
Q3 		$31K Buy
+10,000
New +$37.6K 0.02% 91

Other funds holding SPHS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
AL
Airain Ltd St. Peter Port, Guernsey $2.26B AUM 12.43% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bourgeon Capital Management's SPHS Position: Q4 2016 in Review

Bourgeon Capital Management sold out of Sophiris Bio, Inc. (SPHS) in Q4 2016, closing a stake of 10,000 shares — an estimated $31K sold.

Bourgeon Capital Management first reported a position in SPHS in Q3 2016 and held it in 1 quarter. The position peaked at $31K in Q3 2016. 30 funds tracked by Wall St. Rank hold SPHS as of Q4 2016.

  • Bourgeon Capital Management reported no remaining Sophiris Bio, Inc. position as of Q4 2016 after selling out during the quarter.
  • Bourgeon Capital Management sold 10,000 Sophiris Bio, Inc. shares in Q4 2016, an estimated $31K.
  • Bourgeon Capital Management first reported a position in Sophiris Bio, Inc. in Q3 2016 and held it in 1 quarter.
  • Bourgeon Capital Management's Sophiris Bio, Inc. position peaked at $31K in Q3 2016.
  • 30 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q4 2016.

Based on Bourgeon Capital Management's 13F filing for Q4 2016, filed 27 Jan 2017.